) shares declined after the restaurant chain posted 1.5% lower company restaurant same-store sales for the four weeks ended Aug. 21. The company sees same-store sales for the rest of the year to be down 3% to up 1% for company-owned restaurants. It now sees 2005 earnings per share of $1.33-$1.40, and third quarter earnings per share of 32 cents to 35 cents. Raymond James and Piper Jaffray downgraded their recommendations on the company to market perform from outperform.
) posted second quarter earnings per American Depositary Receipt of 0.39 yuan, vs. 0.06 yuan one year earlier. The company's revenue in the third quarter rose to 77.4 million yuan to 81.2 million yuan, up 139% to 151% compared to the year-earlier quarter.
Seachange International (SEAC
) shares fell after the company posted a second quarter loss per share of 23 cents, vs. 12 cents earnings per share, as revenue fell 39% on a temporary slowdown in the video-on-demand market. Seachange sees lower-than-expected revenue for all of 2006, but believes the second half of the year will be better than the first. Friedman Billings lowered its estimates and price target on the company.
) expanded its existing alliance with Cisco Systems (CSCO
) to improve wireless, security solutions for businesses.
) shares rose after the U.S. Food and Drug Administration approved an amendment to NeoPharm's Special Protocol Assessment, which now includes more analysis from the trial of the drug company's brain cancer medication cintredekin besudotox.
) shares rose after CS First Boston upgraded its rating on the stock to outperform from neutral.
) posted fourth quarter earnings per share of 64 cents, vs. 58 cents, on a 1% same-store sales and 17% total revenue rise. The company sees $2.42 earnings per share in the full year of 2006.
Pilgrim's Pride (PPC
) reaffirmed its 90 cents to $1 earnings per share guidance for the fourth quarter.
) said sales tracking thus far in the first quarter is ahead of its plans, and it now sees sales of at least $445 million and 25 cents earnings per share during the period. The company sees full year sales of about $2.1 billion and minimum earnings per share of $1.25 for all of 2006.
Teva Pharmaceutical (TEVA
) was among a group of generic drug makers that received favorable summary judgments from a New Jersey federal court in patent infringement litigation brought by Pfizer (PFE
) with regard to its anticonvulsant, Neurontin.